NIEL, Belgium, Feb. 24, 2026 /PRNewswire/ -- etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one of its key collaborators, Almirall (), a leading medical dermatology company, nominated LAD116 as a novel therapy targeting non-melanoma skin cancer for further development in IND enabling studies. LAD116 is based on etherna's intratumoral mRNA/LNP platform for therapies intended to generate a potent immu

ESPOO, Finland, Feb. 24, 2026 /PRNewswire/ -- In the field of diagnostics, there has long been a search for solutions to measure low concentrations of small molecules accurately, quickly and easily, for example from food, the environment or a patient sample. VTT has addressed the challenge by developing immunocomplex antibodies. This innovation provides a competitive foundation for next-generation diagnostic solutions. VTT's solution can now also be applied in an easy-to-use testosterone test.

HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. Sciwind

iStock, Andrzej Rostek Billions of dollars’ worth of cancer drugs are discarded each year. Manufacturers must refund Medicare for some of this waste. A data-driven approach offers a practical path to greater efficiency. Research estimates that up to 30% of oncology drugs are discarded each year, representing over $2 billion in annual costs in the United States alone. For pharma companies, discarded drug volumes can reduce realized revenue and, under federal reimbursement policies, may require

BOSTON , Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS ® Plasma Collection System with Persona ® PLUS technology. Persona PLUS represents the next generation of Haemonetics' proprietary and patented Persona technology that tailors plasma collections to each donor fo

iStock, Deagreez Sales of Merck’s longtime oncology blockbuster Keytruda will erode more starkly in about 2033 rather than 2029, predicts Bloomberg Intelligence, translating to some $22 billion more in revenue. As Merck’s oncology juggernaut Keytruda heads toward its curtain call as the highest selling drug, a new analysis from Bloomberg Intelligence suggests that the PD-1 inhibitor could have more exclusivity time than key 2028 patent expirations would suggest. That could mean an additional $2

Achieves 20% worldwide revenue growth and positive adjusted EBITDA for Fiscal Year 2025 Generates free cash flow in the Fourth Quarter 2025 SANTA CLARA, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights (all comparisons a

Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind 1 of $8.1 million. Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds 2 , full year 2025 revenue grew 2% year-over-year. Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12% , Hereditary cancer testing at 9% , a

PRESS RELEASE REDMOND, Wash., Feb 24, 2026 — Today at the ISSAD meeting in Nairobi, Kenya, Prof. Shabir Madhi from the Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit, Johannesburg, South Africa, will present interim results from a clinical study of Inventprise’s hexavalent Group B Streptococcus (GBS) vaccine candidate. The first-in-human, Phase 1/2, randomized, placebo-controlled, observer-blinded study enrolled 600 healthy, non-pregnant women of childbearing age between Nove

iStock, Mariia Bicher The necessity of delivering medicine days after it’s produced drives decisions about where to build facilities and how to ship radioactive materials to healthcare providers. Radiopharmaceutical supply chains are defined by a ticking clock. From the minute an isotope is made, it starts to decay, gradually emitting fewer cancer-killing radioactive particles. The limited half-life of radiopharmaceuticals means the drugs “are like melting ice cubes,” Justin Butler, a partner